• April 2, 2020

Feinstein Institutes begins enrolling patients in multiple COVID-19 clinical trials - Odessa American: Business

e-Edition Subscribe

Feinstein Institutes begins enrolling patients in multiple COVID-19 clinical trials

Print
Font Size:
Default font size
Larger font size

Posted: Friday, March 20, 2020 9:33 am

MANHASSET, N.Y.--(BUSINESS WIRE)--Mar 20, 2020--

The Feinstein Institutes for Medical Research, the research arm of Northwell Health, announced today the enrollment of three clinical trials in the ongoing effort to combat COVID-19, the novel coronavirus.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200320005359/en/

Coronavirus testing lab at Northwell Health (Credit: Northwell Health)

Feinstein Institutes researchers are teaming up with Gilead Sciences, Regeneron Pharmaceuticals and Sanofi to identify effective treatments for patients currently hospitalized in moderate and severe conditions with COVID-19. The goal is to improve recovery and speed discharge from hospitals. The three Feinstein Institutes trials are offered to patients already admitted to Northwell Health hospitals with moderate to severe COVID-19. The trials are not currently available to the general public.

“We’ve joined with three outstanding companies to immediately begin clinical trials for patients now suffering from COVID-19 and are determined to do all we can to stop the virus in its tracks,” said Michael Dowling, president and CEO of Northwell Health.

While there is a nationwide push for an expedited Food and Drug Administration (FDA) approval process of these and other experimental COVID-19 therapies, Northwell Health and the Feinstein Institutes prioritize the safety of patients. The process of these formal trials will lead to accurate testing of these novel drugs prior to mainstream use.

With Gilead, the Feinstein Institutes will conduct two trials looking at the safety and efficacy of remdesivir (RDV), an investigational antiviral drug, designed to reduce the intensity and duration of COVID-19 in hospitalized patients. RDV has demonstrated positive effects on other viral pathogens such as MERS and SARS in vitro and in animal models. The first trial can accommodate up to 400 severe cases of COVID-19 globally and is a randomized study of two different durations of treatment with RDV, delivered intravenously. Researchers will look at clinically relevant endpoints in patients with severe manifestations of disease. The lead investigator on this study is Marcia Epstein, MD, Feinstein Institutes researcher and an infectious disease expert.

The other RDV trial in collaboration with Gilead is also a phase 3 study that will assess two different durations of treatment with RDV as compared to current standard of care in up to 600 patients with moderate COVID-19 globally. Researchers will look at clinical endpoints and time to discharge. The lead investigator on this study is Prashant Malhotra, MD, assistant professor in the Institute of Health Innovations & Outcomes Research at Feinstein, and an infectious disease expert.

In collaboration with Regeneron Pharmaceuticals and Sanofi, the Feinstein Institutes will conduct an adaptive randomized trial for approximately 400 severe or critical patients being hospitalized for the virus in multiple sites across the US. It will look at the safety and efficacy of sarilumab, a human antibody that may prevent the activity of a specific cytokine called interleukin-6 (IL-6) that is thought to be important in the development of complications of severe pneumonia in some COVID-19 patients.

The role of IL-6 is supported by preliminary data from a Chinese trial and based on those results which showed rapid reductions in fever in all patients, China recently updated its COVID-19 treatment guidelines and approved the use of that IL-6 inhibitor to treat patients with severe or critical disease. The study that the Feinstein Institutes will participate in is the first controlled trial in the U.S. to evaluate the effect of IL-6 inhibition prospectively in COVID-19 patients. The lead investigator on this study is Negin Hajizadeh, MD, assistant professor in the Institute of Health Innovations & Outcomes Research at Feinstein, and a pulmonary and critical care physician.

“As history has shown from past pandemics, medical research will lead in our nation’s ability to reverse the fatal spread of viruses,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes. “By teaming up with these outstanding pharmaceutical leaders, our researchers have the opportunity to help beat the Coronavirus by delivering cutting-edge care through clinical research at our Northwell Health hospitals.”

About the Feinstein Institutes

The Feinstein Institutes for Medical Researchis the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 2,500 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit feinstein.northwell.edu.

About Northwell Health

Northwell Health is New York State’s largest health care provider and private employer, with 23 hospitals, about 750 outpatient facilities and more than 13,600 affiliated physicians. We care for over two million people annually in the New York metro area and beyond, thanks to philanthropic support from our communities. Our 70,000 employees – 16,000-plus nurses and 4,000 employed doctors, including members of Northwell Health Physician Partners – are working to change health care for the better. We’re making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Graduate Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Twitter, Instagram and LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200320005359/en/

CONTACT: Matthew Libassi

516-465-8325

mlibassi@northwell.edu

KEYWORD: UNITED STATES NORTH AMERICA NEW YORK

INDUSTRY KEYWORD: MEDICAL DEVICES MEDICAL SUPPLIES INFECTIOUS DISEASES HOSPITALS OTHER HEALTH MANAGED CARE HEALTH PHARMACEUTICAL GENERAL HEALTH

SOURCE: Northwell Health

Copyright Business Wire 2020.

PUB: 03/20/2020 10:33 AM/DISC: 03/20/2020 10:33 AM

http://www.businesswire.com/news/home/20200320005359/en

© 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Sunny
66°
Humidity: 45%
Winds: SW at 12mph
Feels Like: 66°

Your Extended Forecast

Tomorrow

weather
High 86°/Low 56°
Sunny. Highs in the mid 80s and lows in the mid 50s.

friday

weather
High 68°/Low 43°
Times of sun and clouds. Highs in the upper 60s and lows in the low 40s.

saturday

weather
High 59°/Low 50°
Morning showers. Highs in the upper 50s and lows in the low 50s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.